Efficacy of combined treatment of experimental tumors with cytostatic agents and GMDP-A

Objective of the study. To evaluate the pharmacological effects of N-acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-glutamic acid (GMDP-A) as a modifier of biological reactions, i. e. to study its modifying action in regard to traditional cytostatic chemotherapy. Materials and methods. The used drug agents were GMDP-A, cisplatinum, gemcitabine, cyclophosphamide, 5-fluorouracil. The transplanted murine tumors were Р-388 lymphocytic leukemia and S-37 sarcoma (solid and ascites variants), B-16 melanoma, CC-5 squamous cell carcinoma of the cervix uteri, C-26 adenocarcinoma of the colon, and AKATOL carcinoma of the colon (solid tumor variants). Efficacy indices were inhibition of tumor growth, and increase of life span of animals. Results. In the models of transplanted tumors in conventional mice, the influence of GMDP-A has been studied on therapeutic efficacy of cisplatinum (Р-388, S-37, В16, CC-5), 5-fluorouracyl (C-26, AKATOL), gemcitabine and cyclophosphamide (P-388) by using variations in single and total doses, time of the start of the treatment, as well as the route and site of the injection. It has been shown that GMDP-A has modified the efficacy of some cytostatic agents (cisplatinum, gemcitabine and cyclophosphamide) enhancing their antitumor activity irrespective of the location of the site of injection in regard to the tumor node. Conclusion. The obtained results proved the potency of GMDP-A as a modifier of biological reactions.

glucosaminylmuramyldipeptide, modifier of biological reactions, chemotherapy

1. Состояние онкологической помощи населению России в 2014 году. Под ред. А.Д. Каприна, В.В. Старинского, Е.В. Петровой. М.: МНИОИ им. ПА Герцена -филиал ФГБУ «НМИРЦ» Минздрава России, 2015. 236 с.

2. Sorbara M.T., Philpott D.J. Peptidoglycan: a critical activator of the mammalian immune system during infection and homeostasis. Immunol Rev 2011;243 (1):40-60. DOI: 10.1111/j.1600-065X.2011.01047.x. PMID: 21 884 166.

3. Girardin S.E., Boneca I.G., Viala J. et al. NOD2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278 (11):8869-72. DOI: 10.1074/jbc.C200651200. PMID: 12527755.

4. Laman A.G., Lathe R., Savinov G.V. et al. Innate immunity: bacterial cell-wall muramyl peptide targets the conserved transcription factor YB-1. FEBS Lett 2015;589(15):1819-24. DOI: 10.1016/j. febslet.2015.05.028. PMID: 26026270.

5. Lyabin D.N., Eliseeva I.A., Ovchinnikov L. P. YB-1 protein: functions and regulation. Wiley Interdiscip Rev RNA 2014;5(1):95-110. DOI: 10.1002/wrna. 1200. PMID: 24217978.

6. Grimes C.L., Ariyananda L.Z., Melnyk J.E., O’Shea E.K. The innate immune protein NOD2 binds directly to MDP, a bacterial cell wall fragment. J Am Chem Soc 2012;134(33):13535-7. DOI: 10.1021/ja303883c. PMID: 22857257.

7. Meshcheryakova E., Makarov E., Philpott D. Evidence for correlation between the intensities of adjuvant effects and NOD2 activation by monomeric, dimeric and lipophylic derivatives of N-acetylglucosaminyl-N-acetylmuramyl peptides. Vaccine 2007;25(23):4515-20. DOI: 10.1016/j.vaccine.2007.04.006. PMID: 17481783.

8. Pan Q., Mathison J., Fearns C. et al. MDP-induced interleukin-1 beta processing requires NOD2 and CIAS1/NALP3. J Leukoc Biol 2007;82(1):177-83. DOI: 10.1189/jlb.1006627. PMID: 17403772.

9. Windheim M., Lang Ch., Peggie M. et al. Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochem J 2007;404(2):179-90. DOI: 10.1042/BJ20061704. PMID: 17348859.

10. Yang S., Tamai R., Akashi S. et al. Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid 2'2017 том 16 I vol. 16 to induce inflammatory cytokines in human monocytic cells in culture. Infect. Immun. 2001;69(4):2045-53. DOI: 0.1128/IAI. 69.4.2045-2053.2001. PMID: 11254557.

11. Valyakina Т.I., Malakhov A., Malakhova N. et al. Glucosaminylmuramyldipeptide induced changes in phenotype of melanoma cells result in their increased lysis by peripheral blood cells. Int J Oncol 1996;9(5):885-91. PMID: 21541591.

12. Hoos A. Development of immune-oncology drugs - from CTLA4 to PDI to the next generations. Nat Rev Drug Discov 2016;15(4):235-47. DOI: 10.1038/nrd.2015.35. PMID: 26965203.

13. Trescec A., Iskric S., Ljevakovic D. et al. The effects of immunomodulating peptidoglycan monomer and muramyl dipeptide on hepatic microsomal UDP-glucuronyltransferase and beta-glucuronidase. Int J Immunopharmacol 1987;9(3):371-8. DOI: 10.1016/0192-0561(87)90063-4. PMID: 3112033.

14. Козлов И.Г., Воронина Е.В., Валякина Т.И. и др. Ликопид в иммунотерапии опухолей: обзор экспериментальных исследований. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2011;10(2):2-7.

15. Dong Y., Wang S., Wang C. et al. Antagonizing NOD2 signaling with conjugates of Paclitaxel and muramyl dipeptide derivatives sensitizers Paclitaxel therapy and significantly prevents tumor metastasis. J Med Chem 2017;60(3)1219-24. DOI: 10.1021/acs.jmedchem.6b01704. PMID: 28075581.

16. Yoon H.E., Ahn M.Y., Kwon S.M. et al. Nucleotide-binding oligomerization domain 2 (NOD2) activation induces apoptosis of human oral squamous cell carcinoma cells. J Oral Pathol Med 2016;45(4):262-7. DOI: 10.1111 /jop.12354. PMID: 26332444.

17. Петрова Е.Е., Валякина Т.И., Комалева Р.Л. и др. Глюкозаминилмурамилдипептид потенцирует действие ФНО-а и цисплатина на трансформированные клеточные линии in vitro. Бюллетень экспериментальной биологии и медицины 2007;143(2);251-4.

18. Андронова Т.М., Добрушина Е.П., Нижник Е.В. и др. Патент RU № 2 573 991 «Способ получения N-ацетилглюкозаминил-N-ацетил-мурамил-L-аланил-D-глутаминовой кислоты». Опубл. 27.01.2016.

19. Трещалина Е.М., Жукова О.С., Герасимова Г.К. и др. Методические рекомендации по доклиническому изучению противоопухолевой активности лекарственных средств. В кн.: Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К, 2012. С. 642-656.

20. Трещалина Е.М., Жукова О.С., Герасимова Г.К. и др. Методические указания по изучению противоопухолевой активности фармакологических веществ. В кн.: Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. Под общ. ред. Р.У. Хабриева. 2-е изд., перераб. и доп. М.: Медицина, 2005. С. 637-651.